ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

NCT06397703 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

392

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Leuprolide, Degarelix or Relugolix
RADIATION: Stereotactic body radiation therapy/radiosurgery (SBRT)

Sponsor

NYU Langone Health